argenx (ARGX) Stock Forecast & Price Target

argenx is favorably positioned because its commercial franchise around efgartigimod and Vyvgart Hytrulo already has multiple FDA approvals, including gMG in December 2021, the subcutaneous formulation in 2022, and CIDP in 2024, expanding both addressable patients and convenience-driven adoption. Fundamentally, the outlook is supported by a differentiated antibody-engineering platform and a pipeline that is broadening beyond the lead asset into high-value autoimmune indications such as ITP, thyroid eye disease, Sjogren’s disease, and autoimmune myositis, where ALKIVIA met its primary endpoint with a 15.4-point mean total improvement score at 52 weeks and statistically significant separation from placebo as early as week 4. The investment case is further strengthened by evidence of durable clinical activity and a consistent safety profile, with the most common treatment-emergent adverse events being injection site erythema, injection site reaction, and nasopharyngitis, while the company’s growing multi-indication opportunity should support longer-term revenue diversification and higher confidence in execution.

argenx is facing a less compelling risk-reward profile in myositis because the survey suggests only moderate physician conviction for efgartigimod, with expected use of about 26% of eligible DM patients and 24% of eligible IMNM patients in the first 12 months, while awareness remains middling at 5.6/10 and only 12% of physicians reported being contacted by an ARGX representative. Although ALKIVIA delivered a statistically significant IMNM result, the commercial case is softened by meaningful competitive pressure from brepocitinib and CABA-201, plus the fact that physicians often see efgartigimod as a replacement for low-cost oral corticosteroids or IVIG rather than a clearly differentiated first-line standard. The company’s broader dependence on Vyvgart-era expansion also leaves execution risk elevated, since CIDP showed adoption building only gradually from ~5%-7% immediately after approval to ~15%-18% later, implying that without heavier education and stronger differentiation, new indications may take time to convert into decisive revenue momentum.